Can analysts adopt a bullish outlook for Sinclair Pharma plc (LON:SPH)?

June 17, 2018 - By Winifred Garcia

Investors sentiment decreased to 0.85 in Q1 2018. Its down 0.32, from 1.17 in 2017Q4. It fall, as 14 investors sold Sinclair Pharma plc shares while 38 reduced holdings. 16 funds opened positions while 28 raised stakes. 17.28 million shares or 2.47% more from 16.86 million shares in 2017Q4 were reported.
Citadel Advsr Limited Liability Co owns 26,084 shares. Regions Financial, Alabama-based fund reported 8,560 shares. Gsa Capital Ptnrs Llp reported 9,559 shares stake. Goldman Sachs Grp Inc reported 1.06 million shares. Virtu Fincl Limited Liability Corp reported 13,723 shares. Highland Cap Mngmt L P owns 28,222 shares or 0.03% of their US portfolio. Pennsylvania-based Federated Pa has invested 0.01% in Sinclair Pharma plc (LON:SPH). California Employees Retirement Systems stated it has 0% in Sinclair Pharma plc (LON:SPH). Allsquare Wealth Mgmt Lc holds 1,864 shares or 0.03% of its portfolio. M&T State Bank Corp reported 0% in Sinclair Pharma plc (LON:SPH). Barclays Public Ltd Liability Corporation reported 22,748 shares. Brown Brothers Harriman And Com owns 1,000 shares for 0% of their portfolio. 290,981 were accumulated by Tricadia Capital Llc. Glob X Mgmt Ltd invested in 6,566 shares or 0% of the stock. Endurance Wealth Mngmt owns 1,000 shares.

Since February 20, 2018, it had 0 buys, and 2 insider sales for $120,936 activity. Swift Jane also sold $23,600 worth of Sinclair Pharma plc (LON:SPH) on Monday, March 5.

Sinclair Pharma plc (LON:SPH) Ratings Coverage

Among 3 analysts covering Sinclair IS Pharma PLC (LON:SPH), 2 have Buy rating, 0 Sell and 1 Hold. Therefore 67% are positive. Sinclair IS Pharma PLC had 12 analyst reports since January 15, 2018 according to SRatingsIntel. The stock has “Hold” rating by Numis Securities on Thursday, February 22. The firm has “Buy” rating by Peel Hunt given on Thursday, February 22. The firm earned “Buy” rating on Monday, January 15 by Peel Hunt. The stock of Sinclair Pharma plc (LON:SPH) earned “Buy” rating by Peel Hunt on Thursday, May 31. On Monday, April 30 the stock rating was maintained by Peel Hunt with “Buy”. The stock of Sinclair Pharma plc (LON:SPH) earned “Buy” rating by Peel Hunt on Thursday, January 18. As per Monday, April 30, the company rating was maintained by Numis Securities. Peel Hunt maintained Sinclair Pharma plc (LON:SPH) on Wednesday, April 4 with “Buy” rating. The firm earned “Outperform” rating on Monday, April 30 by RBC Capital Markets. Numis Securities maintained Sinclair Pharma plc (LON:SPH) rating on Tuesday, January 16. Numis Securities has “Hold” rating and GBX 21 target. Below is a list of Sinclair Pharma plc (LON:SPH) latest ratings and price target changes.

13/06/2018 Broker: Peel Hunt Rating: Buy Old Target: GBX 42.00 Maintain
31/05/2018 Broker: Peel Hunt Rating: Buy Old Target: GBX 42.00 Maintain
30/04/2018 Broker: Numis Securities Rating: Hold Maintain
30/04/2018 Broker: RBC Capital Markets Rating: Outperform Old Target: GBX 53.00 New Target: GBX 43.00 Maintain
30/04/2018 Broker: Peel Hunt Rating: Buy New Target: GBX 42.00 Maintain
04/04/2018 Broker: Peel Hunt Rating: Buy Old Target: GBX 48.00 Maintain
26/03/2018 Broker: Peel Hunt Rating: Buy Old Target: GBX 48.00 New Target: GBX 48.00 Maintain
22/02/2018 Broker: Numis Securities Rating: Hold Old Target: GBX 21.00 New Target: GBX 21.00 Maintain
22/02/2018 Broker: Peel Hunt Rating: Buy Old Target: GBX 48.00 New Target: GBX 48.00 Maintain
18/01/2018 Broker: Peel Hunt Rating: Buy Old Target: GBX 68.00 New Target: GBX 48.00 Maintain

The stock increased 0.13% or GBX 0.02 during the last trading session, reaching GBX 19.75. About 15,189 shares traded. Sinclair Pharma plc (LON:SPH) has 0.00% since June 17, 2017 and is . It has underperformed by 12.57% the S&P500.

Sinclair Pharma plc, a specialty pharmaceutical company, engages in the manufacture, commercialization, and sale of dermatological products worldwide. The company has market cap of 99.49 million GBP. It provides Silhouette Soft, a resorbable poly-L-lactic acid/PLGA suture with bi-directional resorbable cones for skin repositioning and tightening; and Ellansé, which offers dermal fillers. It currently has negative earnings. The firm also provides Perfectha for wrinkle correction, facial contouring, and volume restoration; and Sculptra designed to stimulate collagen growth.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.